Company
United StatesPublic company, NASDAQ: ARGXargenx BV (NASDAQ: ARGX), Boston, MA – FDA Inspections
Inspection records and compliance data for argenx BV in Boston, Massachusetts. 1 FDA inspection on record, last inspected March 06, 2026. Publicly traded as NASDAQ: ARGX.
Company Profile
This profile covers argenx BV based in Boston, Massachusetts, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 0
- Unclassified
- 1
- Form 483s
- 0
- Warning letters
- 0
Inspected March 6, 2026.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| March 6, 2026 | Not classified | Human Drugs | 1307164 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
argenx BV
Stock ticker
ARGX
Exchange
NASDAQ
Share price
$898.86
Market cap
$55.8B
Price as of
November 6, 2026
FEI Number
3020999966
Address
Boston, Massachusetts 02110, United States
Country
United States
ID: 27704053-aeb2-475c-bbc4-ef6f1cda28ef